Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ivax Launches Neurontin Generic “At Risk” As Pregabalin User Fee Date Nears

Executive Summary

Ivax' "at risk" launch of generic gabapentin comes less than two weeks before the anticipated FDA user fee date for Pfizer's Neurontin follow-on drug Lyrica

You may also be interested in...



Pfizer Recalls One Neurontin Lot; Puerto Rico Plant Still Under Consent Decree

Pfizer is recalling 40,000 bottles of Neurontin (gabapentin) from its Vega Baja, Puerto Rico manufacturing facility after patients reported that capsules of the epilepsy drug were insufficiently filled

Pfizer Recalls One Neurontin Lot; Puerto Rico Plant Still Under Consent Decree

Pfizer is recalling 40,000 bottles of Neurontin (gabapentin) from its Vega Baja, Puerto Rico manufacturing facility after patients reported that capsules of the epilepsy drug were insufficiently filled

Generic Price War Remains Strong; Intensity Is Product Specific, Firms Say

Heavy price competition between generic drugs is product specific and company specific, Andrx President-Generic Business Lawrence Rosenthal said

Related Content

Topics

UsernamePublicRestriction

Register

PS078529

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel